The American Journal of Managed Care
This supplement to contains information on the clinical and economic issues associated with the treatment of enlarged prostate. This supplement has been peer reviewed by experts in the field.
Faculty
Libby Black, PharmDManager
GlaxoSmithKline
Evelyn Chiao, PharmD
Applied Health Outcomes
E. Anne Davis, PharmD, MS
GlaxoSmithKline
Michael T. Eaddy, PharmD, PhD
Applied Health Outcomes
Thomas C. Fenter, MDAssistant Professor of Urology
Medical Center
Blue Cross & Blue Shield of Mississippi
Thomas D. Gilbert, Jr, MS
Milford, Massachusetts
Amy L. Grogg, PharmD
Applied Health Outcomes
Muta M. Issa, MD, MBA
Emory University School of Medicine
Atlanta VA Medical Center
Eric J. Kruep, PharmD, MS
Applied Health Outcomes
Michael James Naslund, MD, MBA
University of Maryland School of Medicine
Maryland Prostate Center
Daniel A. Ollendorf, MPH
PharMetrics, Inc
Manan B. Shah, PharmD, PhD
Applied Health Outcomes
Faculty Disclosures
The American Journal of Managed Care
It is the policy of to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.
These participants report relationships with the following pharmaceutical companies:
Libby Black, PharmD
Employee of:
Speakers' bureau for:
Consultant to:
Michael James Naslund, MD, MBA
Consultant to:
Speakers' bureau/advisory board for:
Speakers' bureau for:
Thomas D. Gilbert, Jr, MS, reports no relevant relationships with pharmaceutical companies.
GlaxoSmithKline provided funding to Applied Health Outcomes to perform research and development related to this manuscript. The following authors are employed by Applied Health Outcomes, which receives grant support from GlaxoSmithKline and other pharmaceutical companies:
The American Journal of Managed Care,
Signed disclosures are on file at the offices of Jamesburg, New Jersey.
This supplement has been supported by funding from GlaxoSmithKline.
---
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.